NeuBase climbs after CEO change
17/01/2024 18:36
** Shares of biotech co NeuBase Therapeutics NBSE.O rise
~4% to 62 cents, set to snap 6-day losing streak
** Co says it terminated CEO Dietrich Stephan without cause
and appointed CFO Todd Branning to the post
** Branning has been serving as the company's finance chief
since January 2022 and will continue in this role during his
tenure as the interim CEO
** Since Stephan took over as CEO in 2019, co's stock has
lost almost all its value; In the last 12 months, it has fallen
89.3%
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on NeuBase Therapeutics
See all newsBrief: Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement
Brief: Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet